Correlation between grading and IDH1 mutation in Indonesian glioma

Dwianingsih, Ery Kus; surename, F. no; Bawono, Rheza Gandi; Rhamadianti, A.F.; Bayuangga, Halwan Fuad; Malueka, Rusdy Ghazali

doi:10.1016/j.jns.2017.08.3306

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Grade IV gliomas 15/44 (34.09%) cases were positive and our results fall within the range that has been reported by others (from 12.5% up to 64.5%) 8,17,29 . This variability may be due to differences in ethnicity, cut off value for IDH1 expression and type of antibody clones used, regarding the correlation of IDH1 with tumor grade; it was statistically highly significant(p-value <0.001) which was in agreement with other studies 17,33 . Another observation in our study was that IDH1 expression not identified in all pilocytic astrocytoma 15(100%) grade I, all grade II ependymoma 4(100%), and all anaplastic ependymoma 4(100%) grade III; a result which was similar to other studies 2,17 confirming that, these tumors are genetically distinct, arising through different mechanisms and may be derived from different type of glial progenitor cells.…”

Section: Table (2): Idh1 Immunoexpression In Different Studiessupporting

confidence: 90%

IDH1(R132H) Immunoexpression in Glioma

Omer¹,

Jalal²,

Ismael³

2018

Adv.med.j.

View full text Add to dashboard Cite

Background and objectives: Gliomas are the most common type of primary brain tumors. They result from accumu-- lation of multiple genetic alterations. Isocitrate dehydrogenase 1 mutations are detected in gliomas. This study aimed to assess IDH1 immunoexpression in different types of gliomas and to correlate the results with patient’s age, gender, tumor site, tumor type and grade. Methods:During the period from January 2015 –January 2017, 97 cases of gliomas were collected from Rizgary Teaching Hospital and private laboratories in Erbil city. Typing and grading of tumors were done according to World Health Organization classification of brain tumors 2007.Immunohistochemical staining was done for IDH1 using monoclonal Antibody IDH1R132. Results: Out of 97 cases of gliomas; 16 were grade I, 27 were grade II, 10 were anaplastic gliomas grade III and 44 cases were glioblastomas; grade IV. Positive IDH1 immunoex- pression was observed in 36 (37.1%) cases of gliomas. The highest prevalence of IDH1 was found in the age group 30-44 years (52.8%), in supratentorial tumors (44.3%) and in grade II and III astrocytoma (72.2% and 75%).Highly significant correlation was found between Isocitrate dehydrogenase 1 expression and age of the patients, tumor type and grade while a significant correlation was found between Isocitrate dehydrogenase 1 expression and tumor site. Conclusions:Our study concluded that Isocitrate dehydrogenase 1 is 36 (37.1%) expressed in gliomas and it is sig- nificantly associated with patient’s age, tumor site, histological type and grade, thus it may act as a good diagnostic and prognostic marker for gliomas.

show abstract

Section: Table (2): Idh1 Immunoexpression In Different Studiessupporting

confidence: 90%

IDH1(R132H) Immunoexpression in Glioma

Omer¹,

Jalal²,

Ismael³

2018

Adv.med.j.

View full text Add to dashboard Cite

show abstract

“…A total of 11 of the 30 samples analyzed turned out to have heterozygous mutations in the 132 IDH1 codon that specifically changed from arginine to histidine; Omer et al [ 17 ], shown a variation in the percentage of mutant IDH1 R132H for gliomas from several countries in Asia such as Japan reported 29.2–31.2%; China 55.2–57.5%; Korea 53.7%; India 41.9%; Iraq 34.86–37.1%. Dwianingsih et al [ 5 ] in 2017, shown that IDH1 mutations are highly identified in Indonesian gliomas patients, as high as 74% (37/50) and significantly correlated with grading. However, in this study, we observed 36.7% (11/25) patients that possess IDH1 R132H mutation and exhibits no significant correlation with grading ( p >0.05), it’s in alignment with what has been observed by others [ 21 , 24 , 27 ]; that stated the IDH1 mutation plays role in tumourigenesis of LGG [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

Analysis of Mutant Isocitrate Dehydrogenase 1 Immunoexpression, Ki-67 and Programmed Death Ligand 1 in Diffuse Astrocytic Tumours : Study of Single Center in Bandung, Indonesia

Bolly

Faried

Hermanto

et al. 2021

J Korean Neurosurg Soc

View full text Add to dashboard Cite

Objective : Diffuse astrocytic tumour (DAT) is a diffuse infiltrative astrocytoma tumour accompanied by molecular parameters such as the presence or absence of isocitrate dehydrogenase (IDH) gene mutations. Ki-67 is a marker for DAT proliferation, while programmed death ligand 1 (PD-L1) indicates an immune evasion mechanism. This study aimed to analyze the correlation among mutant IDH1 R132H, Ki-67, and PD-L1 immunoexpression in the DAT. Methods : A cross-sectional study was carried out on 30 paraffin blocks of DAT cases. Paraffin block samples consist of grade II (n=14), grade III (n=8), and grade IV (n=8). In this study, the immunohistochemistry-staining of mutant IDH1 R132H, Ki-67, and PD-L1 were carried out to determine the frequency of DAT with IDH1 mutations. Results : Our study shown the frequency of IDH1 mutations in grade II 50.0% (7/14), grade III 37.5% (3/8), and grade IV 12.5% (1/8). Our study also showed a difference in Ki-67 and PD-L1 expression between each the degree of DAT histopathology (p=0.0001 and p=0.002, respectively). There was an association between both mutant IDH1 R132H, and Ki-67 with PD-L1 expression in DAT (p=0.0087 and p=0.0049, respectively). Conclusion : DAT with the mutant IDH1 is frequently observed in grade II and small number of grade III. The expression of wild type IDH1, Ki-67, and PD-L1 were found to be higher in high grade DAT (grade III and grade IV). There is a correlation between each of mutant IDH1 status and Ki-67 with PD-L1 expression in DAT.

show abstract

“…R132H for gliomas from several countries in Asia 11 Dwianingsih et al, 12 in 2017, showed that IDH1 mutations are highly identi ed in Indonesian glioma patients, as high as 74% (37/50), and signi cantly correlated with grading. 12,13 Study results suggest that most adult gliomas in Indonesia are wildtype, encouraging demand for adjuvant therapy facilities.…”

Section: Discussionmentioning

confidence: 99%

The Overall Survival Rate Prognosis in Diffuse Astrocytic Patients Based on Isocitrate Dehydrogenase-1 Mutation Status (IDH1 R132H): An Indonesian Multicenter Study

Faried,

Hermanto,

Gill

et al. 2023

Preprint

View full text Add to dashboard Cite

Objective: The IDH1 mutation status is one of the main factors indicated the prognosis of patients with astrocytic malignancies; yet, targeted sequencing is not readily available in countries with limited resources. We aimed to analyze the association between examination IDH1 status and the overall survival rates of diffuse astrocytic tumor patients. Methods: This retrospective cohort multicenter study included 327 diffuse astrocytic tumor patients, January 2017 – December 2022. The immunohistochemistry or PCR data of IDH1 mutation and MGMT status, WHO classification, and Karnofsky performance score (KPS) were collected. Statistical analysis was then performed to analyze their association with the median of follow-up time of 18-months. Result: At 36-month follow-up, the overall survival rate of patients with WHO grade IV (29.23%) was significantly lower than patients with WHO grade III and II (72.24% and 82.46%; p < 0.0001). The diffuse astrocytic tumor patients’ survival rate was also significantly influenced by the KPS score (HR 1.64 [1.08 – 2.50]; p = 0.0208). The survival rate of patients with IDH1 wildtype was significantly lower than that of patients with IDH1 mutant (HR 2.13 [1.51 – 3.00]; p = 0.0004). The overall survival rate of patients with IDH1 wildtype and wildtype MGMT unmethylated was significantly lower than patients with IDH1 mutant MGMT methylated (p < 0.0001). Conclusion: Examination of IDH1-R132H mutant is a reliable examination to predict the survival prognosis in patients with IDH1 mutant vs IDH1 wildtype; this examination could be used as an alternative to the recommended targeted sequencing of IDH1.

show abstract

Correlation between grading and IDH1 mutation in Indonesian glioma

Cited by 4 publications

References 0 publications

IDH1(R132H) Immunoexpression in Glioma

IDH1(R132H) Immunoexpression in Glioma

Analysis of Mutant Isocitrate Dehydrogenase 1 Immunoexpression, Ki-67 and Programmed Death Ligand 1 in Diffuse Astrocytic Tumours : Study of Single Center in Bandung, Indonesia

The Overall Survival Rate Prognosis in Diffuse Astrocytic Patients Based on Isocitrate Dehydrogenase-1 Mutation Status (IDH1 R132H): An Indonesian Multicenter Study

Contact Info

Product

Resources

About